Feb 8, 2024, 05:16
Hagop Kantarjian: A new standard of care in newly diagnosed older FLT3-mutated AML
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:
“Aza + ven + gilteritinib highly effective in newly diagnosed older FLT3-mutated AML: CR/CRi 96% and 18-month OS 72%. A new standard of care in this population.”
Visit the article website.
Source: Hagop Kantarjian/X